Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.42 | Insider Own | 16.26% | Shs Outstand | 218.96M | Perf Week | -4.77% |
| Market Cap | 2.19B | Forward P/E | - | EPS next Y | -1.47 | Insider Trans | -0.21% | Shs Float | 184.90M | Perf Month | -14.83% |
| Enterprise Value | 1.67B | PEG | - | EPS next Q | -0.36 | Inst Own | - | Short Float | 15.17% | Perf Quarter | 5.94% |
| Income | -302.00M | P/S | 42.07 | EPS this Y | -5.36% | Inst Trans | - | Short Ratio | 10.57 | Perf Half Y | 20.80% |
| Sales | 52.00M | P/B | 4.21 | EPS next Y | 1.72% | ROA | -44.90% | Short Interest | 28.06M | Perf YTD | -17.71% |
| Book/sh | 2.37 | P/C | 3.65 | EPS next 5Y | - | ROE | -59.87% | 52W High | 16.44 -39.23% | Perf Year | -17.91% |
| Cash/sh | 2.74 | P/FCF | - | EPS past 3/5Y | - | ROIC | -50.20% | 52W Low | 6.23 60.35% | Perf 3Y | 172.95% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 0.65% 25.06% | Gross Margin | 87.11% | Volatility | 4.81% 4.75% | Perf 5Y | -8.10% |
| Dividend TTM | - | EV/Sales | 32.07 | EPS Y/Y TTM | -16.39% | Oper. Margin | -603.04% | ATR (14) | 0.55 | Perf 10Y | 38.17% |
| Dividend Ex-Date | - | Quick Ratio | 13.03 | Sales Y/Y TTM | -18.75% | Profit Margin | -579.10% | RSI (14) | 45.18 | Recom | 2.05 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.11 | EPS Q/Q | 10.26% | SMA20 | -6.10% | Beta | 0.94 | Target Price | 27.50 |
| Payout | 0.00% | Debt/Eq | 0.12 | Sales Q/Q | 0.00% | SMA50 | 1.24% | Rel Volume | 1.62 | Prev Close | 10.14 |
| Employees | 325 | LT Debt/Eq | 0.12 | Earnings | Nov 03 | SMA200 | 1.09% | Avg Volume | 2.53M | Price | 9.99 |
| IPO Date | Jul 25, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 11.49% 2.07% | Net Debt/EBITDA | 1.82 | Volume | 4,100,611 | Change | -1.48% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-18-26 | Reiterated | Robert W. Baird | $24 → $30 | |
| Jun-18-26 | Reiterated | HC Wainwright & Co. | Buy | $21 → $25 |
| Feb-05-26 | Reiterated | RBC Capital | $30 | |
| Dec-08-25 | Reiterated | HC Wainwright & Co. | Buy | $19 → $21 |
| Oct-08-25 | Reiterated | HC Wainwright & Co. | Buy | $14 → $19 |
| Oct-03-25 | Reiterated | Robert W. Baird | $17 → $24 | |
| Oct-03-25 | Reiterated | Piper Sandler | Overweight | $15 → $31 |
| Oct-01-25 | Reiterated | JMP Securities | Market Outperform | $19 → $29 |
| Mar-04-25 | Reiterated | JMP Securities | Market Outperform | $24 → $19 |
| Aug-08-24 | Reiterated | Robert W. Baird | $18 → $17 |
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 52 | 52 | 64 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 7 | 7 | 6 | — | — | — | — | — | — | |
| Gross Profit | 45 | 45 | 58 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 136 | 118 | 102 | — | — | — | — | — | — | |
| Research and Development | 223 | 197 | 128 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -314 | -270 | -172 | — | — | — | — | — | — | |
| Interest Expense | 12 | 12 | 14 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 24 | 16 | -8 | — | — | — | — | — | — | |
| Net Income Before Taxes | -302 | -266 | -194 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -302 | -266 | -194 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -302 | -266 | -194 | — | — | — | — | — | — | |
| Net Income | -302 | -266 | -194 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.42 | -1.42 | -1.22 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.42 | -1.42 | -1.22 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.42 | -1.42 | -1.22 | — | — | — | — | — | — | |
| EBITDA | -285 | -250 | -176 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 43.23 | 43.66 | 21.08 | — | — | — | — | — | — | |
| Gross Margin | 86.54 | 86.54 | 90.63 | — | — | — | — | — | — | |
| Operating Margin | -603.85 | -519.23 | -268.75 | — | — | — | — | — | — | |
| Net Margin | -580.77 | -511.54 | -303.13 | — | — | — | — | — | — | |
| Shares Outstanding | 225 | 187 | 158 | — | — | — | — | — | — | |
| Market Capitalization | 2,248 | 2,270 | 1,349 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Notman Donald | Chief Operating Officer | Aug 31 '26 | Sale | 10.24 | 1,099 | 11,254 | 366,529 | Sep 02 |
| Heier Jeffrey S. | Chief Scientific Officer | Aug 24 '26 | Sale | 10.78 | 3,296 | 35,531 | 318,326 | Aug 26 |
| Dugel Pravin | See Remarks | Aug 24 '26 | Sale | 10.77 | 21,649 | 233,160 | 2,525,429 | Aug 26 |
| Nayak Sanjay | Chief Strategy Officer | Aug 24 '26 | Sale | 10.78 | 1,897 | 20,450 | 326,898 | Aug 26 |
| Kaiser Peter | Chief Development Officer | Aug 24 '26 | Sale | 10.77 | 3,035 | 32,687 | 264,378 | Aug 26 |
| Waheed Nadia | Chief Medical Officer | Jun 03 '26 | Sale | 8.27 | 14,828 | 122,628 | 300,079 | Jun 05 |
| Kaiser Peter | Chief Development Officer | May 26 '26 | Sale | 8.20 | 2,967 | 24,329 | 266,141 | May 28 |
| Dugel Pravin | See Remarks | May 26 '26 | Sale | 8.20 | 21,156 | 173,479 | 2,597,170 | May 28 |
| Heier Jeffrey S. | Chief Scientific Officer | May 26 '26 | Sale | 8.20 | 3,018 | 24,748 | 320,350 | May 28 |
| Nayak Sanjay | Chief Strategy Officer | May 26 '26 | Sale | 8.20 | 1,858 | 15,236 | 328,795 | May 28 |
| Nayak Sanjay | Chief Strategy Officer | Feb 23 '26 | Sale | 8.28 | 1,759 | 14,565 | 330,653 | Feb 25 |
| Dugel Pravin | See Remarks | Feb 23 '26 | Sale | 8.28 | 20,056 | 166,064 | 3,013,022 | Feb 25 |
| Kaiser Peter | Chief Development Officer | Feb 23 '26 | Sale | 8.28 | 2,810 | 23,267 | 269,108 | Feb 25 |
| Heier Jeffrey S. | Chief Scientific Officer | Feb 23 '26 | Sale | 8.28 | 3,057 | 25,312 | 323,368 | Feb 25 |
| LINDSTROM RICHARD L MD | Director | Feb 20 '26 | Buy | 7.66 | 60,229 | 461,354 | 246,933 | Feb 24 |